Phase 3 study of REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients.
Phase of Trial: Phase III
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Pelareorep (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Oncolytics Biotech
- 20 Sep 2017 New trial record
- 19 Sep 2017 According to an Oncolytics Biotech media release, data of this study will be used for to support a future Biologics License Application (BLA) submission.
- 18 Sep 2017 According to an Oncolytics Biotech media release, company plans to include approximately four hundred patients with a pre-determined interim analysis.